12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BNC105: Interim Phase I/II data

Interim data from the Phase I portion of an open-label, dose-escalation, U.S. Phase I/II trial in patients who failed prior tyrosine kinase inhibitor (TKI) therapy showed that 12.6 mg/m 2 BNC105 plus Afinitor everolimus for >=12 cycles of treatment was well...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >